You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-CDKN2B (CDKN2B) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) Antibodies (CDKN2B)
On www.antibodies-online.com are 135 Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) Antibodies from 17 different suppliers available. Additionally we are shipping CDKN2B Proteins (6) and CDKN2B Kits (2) and many more products for this protein. A total of 153 CDKN2B products are currently listed.
Synonyms:
AV083695, CDK4I, cdk4l, CDKN2A, INK4b, MTS2, p14-INK4b, P15, p15(INK4b), p15INK4b, TP15
list all antibodies Gene Name GeneID UniProt
CDKN2B 1030 P42772
CDKN2B 12579 P55271
CDKN2B 25164 P55272

Show all species

Show all synonyms

Most Popular Reactivities for anti-CDKN2B (CDKN2B) Antibodies

Select your species and application

anti-Human CDKN2B Antibodies:

anti-Mouse (Murine) CDKN2B Antibodies:

anti-Rat (Rattus) CDKN2B Antibodies:

All available anti-CDKN2B Antibodies

Go to our pre-filtered search.

Top referenced anti-CDKN2B Antibodies

  1. Mouse (Murine) Polyclonal CDKN2B Primary Antibody for IF - ABIN181357 : Franklin, Xiong: Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. in Molecular biology of the cell 1997 (PubMed)

  2. Cow (Bovine) Polyclonal CDKN2B Primary Antibody for WB - ABIN2774603 : Scott, Kimura, Dong, Ichinohasama, Bergen, Kerviche, Sheridan, DeCoteau: Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. in Leukemia research 2004 (PubMed)

  3. Human Monoclonal CDKN2B Primary Antibody for IF, IP - ABIN1449282 : Hannon, Beach: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. in Nature 1994 (PubMed)

More Antibodies against CDKN2B Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) interaction partners

  1. Inhibited HO-1 (show HMOX1 Antibodies) expression attenuated the hypermethylation of CDKN2B by suppressing DNMT1 (show DNMT1 Antibodies), which was conducive to treatment by cooperating with decitabine.

  2. The CDKN2A/CDKN2B rs4977756 polymorphism increases the risk of developing glioma in Caucasians. (Meta-analysis)

  3. Data show that KDM5B (show KDM5B Antibodies) is frequently up-regulated in hepatocellular carcinoma tissues and cell lines and correlated with poor prognosis. Its depletion leads to highly impaired clonogenesis and cell cycle arrest through up-regulation of p15 and p27 (show PAK2 Antibodies).

  4. Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A (show CDKN2A Antibodies)/B (CDKN2A (show CDKN2A Antibodies)/B) deletion showed a higher rate of CD20 antigen (show MS4A1 Antibodies) expression.

  5. These results indicate that the inhibitory effect of rapamycin may be due mainly to increased p14 (show S100A9 Antibodies), p15, and p57 (show CDKN1C Antibodies) expression via promoter demethylation and decreased mTOR (show FRAP1 Antibodies) and p70S6K (show RPS6KB1 Antibodies) expression in ALL cell lines.

  6. Tumor suppressor ASXL1 (show ASXL1 Antibodies) is essential for the activation of INK4B expression in response to oncogene (show RAB1A Antibodies) activity and anti-proliferative signals

  7. Point mutations in TP53 (show TP53 Antibodies) but not in p15(Ink4b) and p16(Ink4a (show CDKN2A Antibodies)) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma

  8. Risk alleles for 6 loci increased glucose levels from birth to 5 years of age (ADCY5 (show ADCY5 Antibodies), ADRA2A (show ADRA2A Antibodies), CDKAL1 (show CDKAL1 Antibodies), CDKN2A (show CDKN2A Antibodies)/B, GRB10 (show GRB10 Antibodies), and TCF7L2 (show TCF7L2 Antibodies)

  9. This study investigated the potential roles of CDKN2B-related piRNA in leukemia cells to provide a potential tumorigenesis model of leukemia

  10. Significant associations between single nucleotide polymorphisms in TOX (show TOX Antibodies), CDKN2A (show CDKN2A Antibodies)/B and type 2 diabetes meillitus.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2B (p15, Inhibits CDK4) (CDKN2B) interaction partners

  1. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a (show CDKN2A Antibodies)/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  2. Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta (show TGFB1 Antibodies) signaling and hypoxic neovessel maturation.

  3. Control of CD8 (show CD8A Antibodies) T cell proliferation and terminal differentiation by active STAT5 (show STAT5A Antibodies) and CDKN2A/CDKN2B.

  4. Radiation-induced double strand breaks cooperate with loss of Ink4 (show CDKN2A Antibodies) and Arf (show CDKN2A Antibodies) tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.

  5. When overexpressed in naked mole rat or human cells, pALT(INK4a (show CDKN2A Antibodies)/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a (show CDKN2A Antibodies)).

  6. Cdk4 (show CDK4 Antibodies) and Cdk6 (show CDK6 Antibodies) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (show CDK6 Antibodies) in sequestering INK4 (show CDKN2A Antibodies) proteins away from Cdk4 (show CDK4 Antibodies).

  7. Data indicate that loss of cyclin-dependent kinase inhibitor p15 (p15Ink4b) collaborates with oncogene (show RAB1A Antibodies) fusion protein Nup98 (show NUP98 Antibodies)-HoxD13 (show HOXD13 Antibodies) transgene in the development of predominantly myeloid neoplasms.

  8. Loss of CDKN2B promotes atherosclerosis by increasing the size and complexity of the lipid-laden necrotic core through impaired efferocytosis.

  9. Meningioma progression in mice triggered by Nf2 (show NF2 Antibodies) and Cdkn2ab inactivation.

  10. data demonstrate in vivo that Mule suppresses Ras-mediated tumorigenesis by preventing an accumulation of c-Myc (show MYC Antibodies)/Miz1 (show PIAS2 Antibodies) complexes that mediates p21 (show D4S234E Antibodies) and p15 down-regulation

CDKN2B Antigen Profile

Antigen Summary

This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.

Alternative names and synonyms associated with CDKN2B

  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2B) antibody
  • Cyclin-dependent kinase 4 inhibitor B (cdn2b) antibody
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (cdkn2b) antibody
  • cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) (Cdkn2b) antibody
  • AV083695 antibody
  • CDK4I antibody
  • cdk4l antibody
  • CDKN2A antibody
  • INK4b antibody
  • MTS2 antibody
  • p14-INK4b antibody
  • P15 antibody
  • p15(INK4b) antibody
  • p15INK4b antibody
  • TP15 antibody

Protein level used designations for CDKN2B

Cyclin-dependent kinase 4 inhibitor B , CDK inhibitory protein , CDK4B inhibitor , MTS-2 , cyclin-dependent kinase 4 inhibitor B , cyclin-dependent kinases 4 and 6 binding protein , multiple tumor suppressor 2 , p14-INK4b , p14_CDK inhibitor , p14_INK4B , p15 CDK inhibitor , p15-INK4b , p15_INK4B , cyclin-dependent kinase inhibitor p15 , cyclin-dependent kinase inhibitor p15INK4b , cyclin-dependent kinase inhibitor protein , Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4) , cyclin dependant kinase inhibitor , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2B , cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4) , p15INK4b tumor suppressor

GENE ID SPECIES
709209 Macaca mulatta
100196147 Salmo salar
448767 Xenopus (Silurana) tropicalis
779240 Xenopus laevis
1030 Homo sapiens
12579 Mus musculus
25164 Rattus norvegicus
481563 Canis lupus familiaris
397227 Sus scrofa
527124 Bos taurus
395076 Gallus gallus
Selected quality suppliers for anti-CDKN2B (CDKN2B) Antibodies
Did you look for something else?